Non Hodgkin Lymphoma Clinical Trial
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Summary
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of DLBCL.
Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.
Progression or relapse since most recent therapy.
At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT.
Exclusion Criteria:
Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or central nervous system lymphoma.
Primary refractory disease.
Received an allogenic stem cell transplant.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 14 Locations for this study
Birmingham Alabama, 35294, United States
Scottsdale Arizona, 85259, United States
Los Angeles California, 90095, United States
Palo Alto California, 94305, United States
San Diego California, 92123, United States
Washington District of Columbia, 20007, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60612, United States
Rochester Minnesota, 55905, United States
St. Louis Missouri, 63110, United States
New York New York, 10021, United States
Charleston South Carolina, 29403, United States
Seattle Washington, 98104, United States
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.